OR WAIT 15 SECS
The company completed its oral solid dose production facility in Suzhou, China.
Eisai announced in a Jan. 11, 2018 press release that its Chinese subsidiary, Eisai China, has completed construction of a new oral solid dose (OSD) production facility and an administration building at the site of its new Suzhou plant located within the Suzhou Industrial Park.
The newly completed facility stands three floors aboveground, contains floor space of approximately 20,240 m2, and its production capacity of approximately 3 billion tablets per year and packaging for 5 billion tablets per year is approximately double that of the current Suzhou plant.
According to the company, it has been working to establish a new Suzhou plant on a new industrial site more than five times larger than the current Suzhou plant.
The new facility will handle the formulation and packaging of OSD products including Methycobal, Aricept, and Pariet for the domestic Chinese market. Operations are expected to commence in the second half of fiscal 2018. The current plant will be closed after operations fully commence at the new facility.